Edition:
India

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

1.76USD
22 Mar 2019
Change (% chg)

$0.04 (+2.33%)
Prev Close
$1.72
Open
$1.70
Day's High
$1.79
Day's Low
$1.70
Volume
31,676
Avg. Vol
73,830
52-wk High
$2.92
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Infinity Pharmaceuticals Inc Files For Mixed Shelf Of Upto $100 Mln
Thursday, 14 Mar 2019 

March 14 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Infinity Pharmaceuticals Expects Net Loss For 2019 To Range From $30 Mln To $40 Mln
Thursday, 14 Mar 2019 

March 14 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.INFINITY PHARMACEUTICALS INC - INFINITY EXPECTS NET LOSS FOR 2019 TO RANGE FROM $30 MILLION TO $40 MILLION..INFINITY PHARMACEUTICALS - EXPECTS TO END 2019 WITH YEAR-END CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES BALANCE RANGING FROM $40 MILLION-$50 MILLION.INFINITY PHARMACEUTICALS - SEES EXISTING CASH, CASH EQUIVALENTS, AVAILABLE-FOR-SALE SECURITIES WILL BE ADEQUATE TO SATISFY CO'S CAPITAL NEEDS INTO 2H 2020.  Full Article

Infinity To Initiate Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer
Thursday, 14 Mar 2019 

March 14 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY TO INITIATE MARIO-3, A PHASE 2 MULTI-ARM STUDY EVALUATING IPI-549 IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER AND RENAL CELL CANCER.INFINITY PHARMACEUTICALS - CO ENTERS MASTER CLINICAL SUPPLY AGREEMENT WITH ROCHE TO PROVIDE ATEZOLIZUMAB FOR MARIO-3.INFINITY PHARMACEUTICALS - MARIO-3 WILL EVALUATE IPI-549 WITH TECENTRIQ AND ABRAXANE IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER.INFINITY PHARMACEUTICALS - MARIO-3 WILL ALSO EVALUATE IPI-549 WITH TECENTRIQ AND AVASTIN IN FRONT-LINE RENAL CELL CANCER.INFINITY PHARMACEUTICALS - UNDER TERMS, ROCHE WILL SUPPLY ATEZOLIZUMAB TO INFINITY FOR USE IN MARIO-3, A PHASE 2 MULTI-ARM COMBINATION COHORT STUDY.  Full Article

Infinity Pharmaceuticals Announces Royalty Monetization Of COPIKTRA For $30 Mln Gross Proceeds
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS ANNOUNCES ROYALTY MONETIZATION OF COPIKTRA FOR $30 MILLION GROSS PROCEEDS.INFINITY PHARMACEUTICALS INC - ANNOUNCED ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS (HCR) FOR RIGHT TO RECEIVE CERTAIN ROYALTY PAYMENTS.INFINITY PHARMACEUTICALS INC - ROYALTY PAYMENTS BASED ON WORLDWIDE ANNUAL NET SALES OF COPIKTRA (DUVELISIB), PAYABLE BY VERASTEM.INFINITY PHARMACEUTICALS - UNDER AGREEMENT, HCR HAS AGREED TO PAY CO A $30 MILLION UPFRONT PAYMENT AND UP TO $20 MILLION IN POTENTIAL MILESTONE PAYMENTS.INFINITY PHARMACEUTICALS INC - IN CONNECTION WITH ROYALTY MONETIZATION, INFINITY ENTERED INTO AN AMENDMENT OF ITS LICENSE AGREEMENT WITH TAKEDA.INFINITY PHARMACEUTICALS - AS PER AMENDMENT OF LICENSE AGREEMENT WITH TAKEDA, TAKEDA HAS AGREED TO RECEIVE A PORTION OF TOTAL INVESTMENT AMOUNT.  Full Article

Infinity Pharmaceuticals Provides 2019 Goals And Financial Guidance
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS PROVIDES 2019 GOALS AND FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS - INFINITY PLANS TO INITIATE MARIO-275 STUDY IN FIRST HALF OF 2019.INFINITY PHARMACEUTICALS INC -SEES 2019 NET LOSS BETWEEN $30 MILLION TO $40 MILLION.INFINITY PHARMACEUTICALS - HAS CASH RUNWAY INTO 2H2020, WHICH ENABLES CO TO ADVANCE IPI-549 DEVELOPMENT IN SEVERAL INNOVATIVE STUDIES IN 2019.  Full Article

Infinity Pharma Earns $22 Mln Payment From Verastem Oncology For FDA Approval Of Copiktra (Duvelisib) And Updates 2018 Financial Guidance
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS EARNS $22 MILLION PAYMENT FROM VERASTEM ONCOLOGY FOR FDA APPROVAL OF COPIKTRA™ (DUVELISIB) AND UPDATES 2018 FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS INC - EXPECTS NET LOSS FOR 2018 TO RANGE FROM $10 MILLION TO $20 MILLION..INFINITY PHARMACEUTICALS - EXPECTS TO END 2018 WITH YEAR-END CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES BALANCE RANGING $50 MILLION TO $60 MILLION.INFINITY PHARMACEUTICALS - SEES EXISTING CASH, CASH EQUIVALENTS, AVAILABLE-FOR-SALE SECURITIES TO BE ADEQUATE TO SATISFY CAPITAL NEEDS INTO 2020.  Full Article

Arcus Biosciences, Infinity Pharmaceuticals Enter Clinical Collaboration To Evaluate Two Triple Combination Therapies In Selected Tumor Types
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Infinity Pharmaceuticals Inc ::ARCUS BIOSCIENCES AND INFINITY PHARMACEUTICALS ANNOUNCE CLINICAL COLLABORATION TO EVALUATE LEAD PROGRAMS IN TRIPLE-COMBINATION STUDIES.INFINITY PHARMACEUTICALS - CO, ARCUS BIOSCIENCES ENTER CLINICAL COLLABORATION TO EVALUATE TWO TRIPLE COMBINATION THERAPIES IN SELECTED TUMOR TYPES.INFINITY PHARMACEUTICALS INC - COLLABORATION WILL EVALUATE IPI-549 IN COMBINATION WITH AB928 AND AB122.INFINITY PHARMACEUTICALS - COLLABORATION TO ALSO EVALUATE IPI-549 WITH AB928 & CHEMOTHERAPY IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER/OVARIAN CANCER.INFINITY PHARMACEUTICALS INC - INFINITY AND ARCUS WILL SHARE EQUALLY EXPENSES RELATED TO FOUR TRIPLE-COMBINATION COHORTS.INFINITY PHARMACEUTICALS INC - TOPLINE DATA FROM THE STUDIES ARE EXPECTED IN 2019.  Full Article

Infinity Pharmaceuticals Q1 Loss Per Share $0.18
Wednesday, 9 May 2018 

May 8 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.INFINITY PHARMA - BELIEVES EXISTING CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES WILL BE ADEQUATE TO SATISFY FORECASTED OPERATING NEEDS INTO Q3 2019.INFINITY PHARMACEUTICALS - EXPECTS TO CONTINUE TO "INCUR SIGNIFICANT OPERATING LOSSES FOR THE FORESEEABLE FUTURE".  Full Article

Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing
Tuesday, 1 May 2018 

April 30 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 1.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
Friday, 13 Apr 2018 

April 12 (Reuters) - Biotechnology Value Fund LP::BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING.BVF PARTNERS SAYS PURCHASED INFINITY PHARMACEUTICALS SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article